<html>
<head>
  <title>PD1/PDL1免疫治疗介绍</title>
  <basefont face="微软雅黑" size="2" />
  <meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
  <meta name="exporter-version" content="YXBJ Windows/600753 (zh-CN, DDL); Windows/10.0.0 (Win64);"/>
  <style>
    body, td {
      font-family: 微软雅黑;
      font-size: 10pt;
    }
  </style>
</head>
<body>
<a name="452"/>
<h1>PD1/PDL1免疫治疗介绍</h1>

<div>
<span><div><h1>PD1/PDL1免疫治疗介绍</h1><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; position: relative; letter-spacing: 0.5px; margin: 17px 0px 3px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><div><a href="http://www.360kuai.com/pc/9ba50ced5e208a672?cota=4&amp;tj_url=so_rec&amp;sign=360_57c3bbd1&amp;refer_scene=so_1">http://www.360kuai.com/pc/9ba50ced5e208a672?cota=4&amp;tj_url=so_rec&amp;sign=360_57c3bbd1&amp;refer_scene=so_1</a></div><div>        默沙东PD-1单抗Keytruda(帕博利珠单抗)与百时美施贵宝Opdivo(欧狄沃单抗)相继在中国上市。免疫治疗肿瘤已是新兴的疗法，其疗效相比其他传统疗法有过之而无不及。于是乎很多人会问PD-1和PD-L1的区别，大家看到这两个单词都很相似很容易混淆，在此给大家扫盲，看完下面两个视频大家会很清楚之间的区别，并且汇总国内外PD-1/PD-L1的研究现状。</div><div><span style="color: rgb(227, 0, 0);">PD-1(programmed death 1)：</span>程序性死亡受体1，是一种重要的免疫抑制分子。为CD28超家族成员,其最初是从凋亡的小鼠T细胞杂交瘤2B4.11克隆出来。以PD-1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植存活等均有重要的意义。其配体PD-L1也可作为靶点，相应的抗体也可以起到相同的作用。由日本京都大学本庶佑教授于1992年发现。</div><div><span style="color: rgb(227, 0, 0);">PD-L1( programmed cell death-Ligand 1)：</span>程序性死亡受体-配体1，是大小为 40kDa 的第一型跨膜蛋白，据信其在某些特殊情形(例如怀孕、组织移植、自体免疫疾病，以及诸如肝炎等某些疾病)下，免疫系统的抑制有关。正常情形下免疫系统会对聚集在淋巴结或脾脏的外来抗原产生反应，促发具抗原特异性的细胞毒杀性T细胞(CD8+ Tcell增生)。而细胞程序化死亡受体-1(PD-1)与细胞程式死亡-配体1(PD-L1)结合，可以传导抑制性的信号，减低淋巴结CD8+ T细胞的增生， 而且PD-1还可以借由调节Bcl-2基因，控制淋巴结中抗原特异性T细胞的聚积。由中国科学家陈列平(LiepingChen)教授于1999年发现。</div><div>        肿瘤免疫疗法，PD1单克隆抗体，PDL1单克隆抗体，这些名词经常被提起，经常能听到。光看上述的两个概念，很多人可能仍然是云里雾里。我们谨以上两个视频来解说，免疫细胞T细胞，就好比是我们人体内四处巡逻的“警卫队”，当我们感染外来病原体或罹患肿瘤时，它能立刻识别并启动杀伤防御系统，控制疾病保护机体。但是呢，肿瘤细胞也是非常狡猾的。一些肿瘤细胞会携带有一些起到“面具”作用的蛋白质，当它们与正常细胞混在一起，就可以躲避T细胞的捕捉了。而所谓的PD-L1就是这些具有“面具”作用的蛋白之一。</div><div>        当PD-1和PD-L1结合之后，T细胞遇见肿瘤细胞就会手下留情，非但不会杀死肿瘤细胞，甚至让肿瘤细胞继续在人体内休养生息。也就是说，如果我们可以想出一些办法阻止PD-1和PD-L1的相遇和结合，那么肿瘤细胞仍然难逃灭亡的厄运!基于这一机制，科学家们灵机一动，如果以PD-1或PDL1为靶点设计合成出一些抗体制剂(人源性单克隆抗体制剂)分别与PD1或PDL1蛋白结合，就能阻断原来两个蛋白的彼此连接，从而就能打断这一通路，那么T细胞就不会被蒙蔽双眼而出现消极怠工的现象，从而可以让T细胞重新对肿瘤细胞发起总攻。也就是说，有了这些单克隆抗体，肿瘤细胞的好日子总算是到头啦!</div><div>        国外PD-1/PD-L1的研究现状，数百项关于抗PD-1和PD-L1单克隆抗体的临床试验正在积极开展中，其中一些已经进入3期临床试验。FDA已经批准了部分针对一系列人类癌症的抗PD-1和PD-L1单克隆抗体，并且使许多患者受益。</div><div>目前，全球已经有5种PD-1/PD-L1抑制剂获批上市，包括</div><div><span style="color: rgb(227, 0, 0);">默沙东的Pembrolizumab(Keytruda®)、百时美施贵宝的Nivolumab(Opdivo®)、</span></div><div><span style="color: rgb(227, 0, 0);">罗氏的Atezolizumab(Tecentriq®)、辉瑞/默克的Avelumab(Bavencio®)、阿斯利康的Durvalumab(Imfinzi®)，前两个是PD-1抑制剂，其它是PD-L1抑制剂。</span></div><div><span style="font-size: 12pt; color: rgb(227, 0, 0);"><img src="PD1PDL1免疫治疗介绍_files/Image.png" type="image/png" data-filename="Image.png"/></span></div><div><span style="font-size: 12pt;"><br/></span></div><div><span style="font-size: 12pt;"><br/></span></div><div><span style="font-size: 12pt; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;;">术语须知：</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">OS：总生存期(overall survival)</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">PFS：无进展生存期(progression-free survival)</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">DCR：疾病控制率(disease control rate),</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">DCR=CR+PR+SD.</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">ORR：客观缓解率(Objective Response Rate)</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">OR</span><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">：</span> <span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">总缓解率 (overall response 或者 overall remission)</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">PD</span><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">：</span> <span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">疾病进展(progression disease)</span></div><div><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">MTD</span><span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">：</span> <span style="font-size: 16px; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: pre-wrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Lantinghei SC&quot;, &quot;Microsoft YaHei&quot;, arial; font-variant-caps: normal; font-variant-ligatures: normal;">最大耐受剂量(maximum tolerated dose)</span></div><div><span style="font-size: 12pt;">HR：</span></div><div><span style="font-size: 12pt;">DOR：</span></div><div><span style="font-size: 12pt;">TPS：</span></div><div><span style="font-size: 12pt;"><br/></span></div><div><span style="font-size: 12pt;">CR：</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">完全缓解(CR)，肿瘤完全消失超过1个月。（</span> <span style="font-size: 12pt; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;;">complete response</span><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">）</span></div><div><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">PR：</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">部分缓解(PR)，肿瘤最大直径及最大垂直直径的乘积缩小达50%，其他病变无增大，持续超过1个月。（</span><span style="font-size: 12pt; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;;">partial respons</span><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">）</span></div><div><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">SD：</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">病变稳定(SD)，病变两径乘积缩小不超过50%，增大不超过25%，持续超过1个月.</span><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">（</span><span style="font-size: 12pt; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;;">stable disease</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">）</span></div><div><span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">PD：</span> <span style="font-size: 16px; letter-spacing: 0.5px; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(51, 51, 51); font-family: &quot;PingFang SC&quot;, &quot;Hiragino Sans GB&quot;, &quot;Microsoft YaHei&quot;, &quot;WenQuanYi Micro Hei&quot;, &quot;Helvetica Neue&quot;, Arial, sans-serif; font-variant-caps: normal; font-variant-ligatures: normal;">病变进展(PD)，病变两径乘积增大超过25%.</span></div><div><span style="font-size: 12pt;"><br/></span></div><div><span style="font-size: 12pt; color: rgb(227, 0, 0);">(一)国外已上市的PD-1抑制剂</span></div><div>Pembrolizumab(Keytruda®)</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 375px;"></col><col style="width: 375px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>临床试验数据</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>非小细胞肺癌(NSCLC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>Keytruda+卡铂+培美曲塞组的ORR为55%，卡铂+培美曲塞组为29%;Keytruda+卡铂/培美曲塞组的中位PFS为13个月，卡铂/培美曲塞组为8.9个月;与单独化疗相比，Keytruda加化疗的组合显著改善了OS，死亡风险降低36%，HR = 0.64;DOR≥6个月的占93%;TPS≥50%、TPS≥20%、TPS≥1%的中位OS分别为20.0个月(vs化疗组12.2个月)、17.7个月(vs化疗组13.0个月)和16.7个月(vs化疗组12.1个月)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>黑色素瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>未达到中位OS，Yervoy组为16.0个月，Keytruda组显著改善OS，HR=0.68，P无统计学差异;半年PFS率为46%，Yervoy组为27%;ORR为34%(CR=6%，PR=27%)，Yervoy组ORR为12%(CR=1%，PR=10%)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>头颈部鳞状细胞癌(HNSCC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为16%(CR=5%，PR=11%)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性尿路上皮癌(mUC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为29%(CR=7%，PR=22%)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>胃癌或胃食管交界处癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为13.3%(CR=1.4%，PR=11.9%);DOR为2.8+~19.4+个月，58%的DOR＞6个月，26%的DOR＞12个月</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>经典霍奇金淋巴瘤(cHL)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为69%(CR=22%，PR=47%);中位DOR为11.1个月</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>纵膈大B细胞淋巴瘤(PMBCL)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为45%(CR=11%，PR=34%)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>MSI-H/dMMR</div><div>晚期实体瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>(1)结直肠癌</div><div>ORR为36%</div><div>(2)其它实体瘤</div><div>ORR为46%</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>晚期宫颈癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为14.3%(CR=2.6%，PR=11.7%);91%的DOR＞6个月</div></td></tr></tbody></table><div><br/></div></div><div>Nivolumab(Opdivo®)</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 375px;"></col><col style="width: 375px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>临床试验数据</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>非小细胞肺癌(NSCLC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>(1)非鳞非小细胞肺癌</div><div>中位OS为12.2个月，多西他赛组9.4个月;一年生存率为51%，多西他赛组39%;ORR为19%(56/292; 4例完全缓解)，多西他赛组为12%(36/290; 1例完全缓解);中位DOR为17个月，多西他赛组为6个月;中位PFS为2.3个月，多西他赛组为4.2个月</div><div>(2)鳞状非小细胞肺癌</div><div>ORR为20%(27/135; 1例完全缓解)，多西他赛组为9%(12/137; 0例完全缓解);一年生存率为42%，多西他赛组为24%;未达到DOR，多西他赛组为8.4个月;中位PFS为3.5个月，多西他赛组为2.8个月;与多西他赛组相比，Opdivo组的死亡风险降低了41%</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>黑色素瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>(1)BRAF WT和BRAF MT转移性黑色素瘤(一线治疗)</div><div>Opdivo+Yervoy组的中位PFS为11.5个月，Opdivo组为6.9个月，Yervoy组为2.9个月;Opdivo+Yervoy组ORR为50%(CR=8.9%，PR=41%)，Opdivo组ORR为40%(CR=8.5%，PR=31%)，Yervoy组为14%(CR=1.9%，PR=12%)</div><div>(2)BRAF V600 WT 转移性黑色素瘤(一线治疗)</div><div>中位OS未达到，达卡巴嗪组为10.8个月，HR=0.42，P值无统计学差异;中位PFS为5.1个月，达卡巴嗪组为2.2个月，HR=0.43，P值无统计学差异;ORR为34%(CR=4%，PR=30%)，达卡巴嗪组为9%(CR=1%，PR=8%);一年生存率为73%，达卡巴嗪组为42%</div><div>(3)接受全面切除淋巴结(III期)或转移性(IV期)的黑色素瘤(辅助治疗)</div><div>18个月RFS为66.4%，Yervoy组为52.7%;Opdivo组复发风险降低35%</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>头颈部鳞状细胞癌(HNSCC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>一年生存率为36%，标准治疗组为17%;PFS的HR为0.89;ORR为13.3%，标准治疗组为5.8%</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>肾细胞癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>(1)中/低风险的晚期肾细胞癌(一线治疗)</div><div>Opdivo+Yervoy组的中位OS尚未达到，舒尼替尼为25.9个月;Opdivo+ Yervoy组ORR为41.6%(177/425; CR=9.4%[n = 40]，PR=32.2%[n = 137])，舒尼替尼组为26.5%(112/422; CR=1.2%[n = 5]; PR=25.4%[n = 107])(P</div><div>(2)先前用过抗血管生成疗法治疗的晚期肾细胞癌</div><div>中位OS为25个月，依维莫司组为9.6个月，HR=0.73;ORR为21.5%，依维莫司组为3.9%;DOR为23.0%，依维莫司组为13.7%;长期随访:两年生存率为52%(vs 42%)，三年生存率为39%(vs 30%)，三年中位OS为25.8个月(vs 19.7个月)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性尿路上皮癌(mUC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为19.6%，其中PD-L1表达≥1%的患者(31/124)ORR为15.1%，PD-L1表达&lt;1%(22/146)的为25%;中位DOR为 10.3个月</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>肝细胞癌(HCC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为18.2%(28/154)，CR=3.2%(5/154)，PR=14.9%(23/154);在PD-L1非表达者和表达者中均观察到总体响应;中位DOR为16.6个月，其中持续时间≥6个月的有91%，持续时间≥12个月有55%;中位响应时间为2.8个月</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>MSI-H/dMMR结直肠癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为32%(CR=2.7%，PR=30%)，先前用奥沙利铂、氟嘧啶、伊立替康治疗过的患者ORR为28%(CR=1.9%，PR=26%);DOR均未达到</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>经典霍奇金淋巴癌(cHL)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>在自体造血干细胞移植(HSCT)治疗后复发或有疾病进展的患者，ORR为69%(CR=14%，PR=55%);在自体造血干细胞移植(HSCT)和brentuximab vedotin治疗后复发或有疾病进展的患者，ORR为66%(CR=6%，PR=60%)，中位DOR为13.1个月</div></td></tr></tbody></table><div><br/></div></div><div><span style="font-size: 12pt; color: rgb(227, 0, 0);">(二)国外部分在研PD-1抑制剂</span></div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 187px;"></col><col style="width: 187px;"></col><col style="width: 187px;"></col><col style="width: 187px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>药物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>药厂</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>临床试验阶段</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>适应症</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Cemiplimab(REGN2810)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>再生元、</div><div>赛诺菲</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>复发或转移性铂类难治性宫颈癌(临床Ⅲ期);晚期皮肤鳞状细胞癌、黑色素瘤和其他皮肤恶性肿瘤(Ⅱ期)等</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>AMP-224</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>阿斯利康</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>结直肠癌等</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>MEDI0680(AMP-514)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>阿斯利康</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>透明细胞性肾细胞癌等</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>PDR-001</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>诺华</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>三重阴性乳腺癌;胰腺癌;</div><div>黑色素瘤;子宫内膜癌等</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>BCD-100</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Biocad</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>黑色素瘤、非小细胞肺癌</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>TSR-042</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Tesaro</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>JNJ-63723283</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>强生</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>多发性骨髓瘤、前列腺癌、尿路上皮癌</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>PF-06801591</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>辉瑞</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>BI-754091</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>勃林格殷格翰</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤</div></td></tr></tbody></table><div><br/></div></div><div><span style="font-size: 12pt; color: rgb(227, 0, 0);">(三)国外已上市的PD-L1抑制剂</span></div><div>Atezolizumab(Tecentriq®)</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 375px;"></col><col style="width: 375px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>临床试验数据</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>非小细胞肺癌(NSCLC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>中位OS为13.8个月，多西他塞组为9.6个月;一年生存率为55%，多西他塞组为41%;18个月生存率为40%，多西他塞组为27%;中位DOR为16.3个月，多西他塞组为6.2个月;ORR为14%，多西他塞组为13%;中位PFS为2.8个月，多西他塞组为4.0个月，HR=0.95</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性尿路上皮癌(mUC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为23.5%(CR=6.7%，PR=16.8%)</div></td></tr></tbody></table><div><br/></div></div><div>Avelumab(Bavencio®)</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 375px;"></col><col style="width: 375px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>临床试验数据</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性梅克尔细胞癌(mMCC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为33%(CR=11%，PR=22%);DOR＞6个月的有86%，DOR＞12个月的有45%</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性尿路上皮癌(mUC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR＞13个星期的有30%，CR的有9%，PR的有21%;ORR＞6个月的有26%(CR＞6个月的有9%，PR＞6个月的有17%)</div></td></tr></tbody></table><div><br/></div></div><div>Durvalumab(Imfinzi®)</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 375px;"></col><col style="width: 375px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>临床试验数据</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>非小细胞肺癌(NSCLC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>中位PFS为16.8个月，安慰剂组为5.6个月;与安慰剂组相比，进展或死亡风险的减少48%，HR = 0.52;12个月PFS为56%，安慰剂组为35%;18个月PFS为44%，安慰剂组为27%;ORR 为26%(CR=1%、PR=25%)，安慰剂组为14%(CR=0%、PR=14%)</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>转移性尿路上皮癌(mUC)</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 375px; padding: 8px;"><div>ORR为17%(CR=2.7%，PR=14.3%)，先前接受铂类治疗后的患者ORR为24%;中位DOR为6个星期</div></td></tr></tbody></table><div><br/></div></div><div><span style="font-size: 12pt; color: rgb(227, 0, 0);">(四)国外部分在研PD-L1抑制剂</span></div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 187px;"></col><col style="width: 187px;"></col><col style="width: 187px;"></col><col style="width: 187px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>药物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>药厂</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>临床试验阶段</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>适应症</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>M7824</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>默克</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>CX-072</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>CytomX Therapeutics</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>FAZ-053</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>诺华</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>非小细胞肺癌，三阴性乳腺癌，子宫内膜癌等</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>LY-3300054</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>礼来</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>非小细胞肺癌、头颈部鳞状细胞癌</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>CA-170</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Curis</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 187px; padding: 8px;"><div>实体瘤、淋巴瘤</div></td></tr></tbody></table><div><span style="font-size: 12pt; color: rgb(255, 0, 0);">(五) 国内PD-1/PD-L1的研究现状</span></div></div><div>国内对PD-1/PD-L1抑制剂的研发起步较晚，但目前也呈现出蓬勃发展的势头，已经有十多家药厂的PD-1抑制剂(PD-1抗体、PD-L1抗体)进入临床试验或者即将进入临床试验。其中，信达、君实和恒瑞PD-1抗体的上市申请已经获得了国家药监局受理，有望尽快上市。</div><div>另外，除了已经率先在中国上市的纳武利尤单抗，其他4个已被FDA批准的PD-1/PD-L1抑制剂也正在中国开展临床试验，相信很快能够得到CFDA的批准，造福中国患者。</div><div>国内在研PD-1/PD-L1抑制剂</div><div style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; margin-bottom: 16px;"><div><br/></div><table style="border-collapse: collapse; min-width: 100%;"><colgroup><col style="width: 150px;"></col><col style="width: 150px;"></col><col style="width: 150px;"></col><col style="width: 150px;"></col><col style="width: 150px;"></col></colgroup><tbody style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>药名</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>药厂</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>临床试验阶段</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>适应症</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>靶点</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>SHR-1210</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>恒瑞医药</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>胃癌或胃食管交界处癌;经二线及以上化疗失败的复发或转移的鼻咽癌;晚期肝细胞癌等</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>JS001</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>君实生物、君盟生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>复发性或转移性鼻咽癌;晚期或复发伴EGFR敏感突变、T790M阴性非小细胞肺癌等</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>BGB-A317</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>百济神州</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>非小细胞肺癌、食管鳞癌、肝细胞癌等</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div><br/></div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>IBI308</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>信达生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期的或转移性鳞状非小细胞肺癌等</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>GB226</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>嘉和生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期和/或复发实体瘤/淋巴瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>GLS-010</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>誉衡制药、药明康德</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期实体瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>LZM009</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>丽珠医药</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期实体瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>HX008</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>翰中生物、翰思生物</div><div>、康方生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>局部晚期或转移性实体瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>SHR-1316</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>恒瑞医药</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期恶性肿瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-L1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>KN035</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>康宁杰瑞、思路迪生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅲ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>晚期实体瘤;不能手术切除或转移性的胆道癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-L1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>ZKAB001</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>兆科药业</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>骨肉瘤;尿路上皮癌</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-L1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>CS1001</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>基石生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ/Ⅱ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>复发或难治性结外自然杀伤细胞/T细胞淋巴瘤等</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-L1</div></td></tr><tr style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear;"><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>BAT1306</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>百奥泰生物</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>Ⅰ期</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>实体瘤</div></td><td style="transition: margin 0.1s linear, padding 0.1s linear, width 0.1s linear, height 0.1s linear; text-align: center; border: 1px solid rgb(102, 102, 102); width: 150px; padding: 8px;"><div>PD-L1</div></td></tr></tbody></table><div><br/></div></div><div>目前，国内外药企都在火速推进各自的临床项目，正在研究PD-1/PD-L1抑制剂的单药疗法和组合疗法用于多种癌症的治疗，以彻底发掘该类药物的最大临床潜力。另外，对于已经上市的几个PD-1药物，研究人员也在积极地进行临床试验以拓展其适应症，以及研究相关的联合疗法。</div><div>国内药企虽然研究起步较晚，但是国内多项临床试验以及国际IND申报正在进行，相信很快会有中国研制的第一个PD-1/PD-L1抑制剂上市。我们也希望看到更多的患者由此获益，共同见证PD-1的神奇疗效。</div></div><div><br/></div></div><div><br/></div></span>
</div></body></html> 